In our ongoing efforts to be responsive to readers, we introduce in this issue a new feature, the Point-Counterpoint series. These articles will publish as the need arises and will feature major controversies with the opposing points of view presented by their major proponents in two full length articles. In this issue, two of the leading investigators in the area of pharmacokinetics and drugdrug interactions, Lindsay DeVane of the Medical University of South Carolina and Sheldon Preskorn of the University of Kansas School of Medicine in Wichita, debate the issue of drug-drug interactions and their clinical relevance in treating patients with antidepressants. This format consists of original overviews by each proponent summarizing the evidence for their view, followed by rebuttals by each prepared in response to the other's summary of the literature.
We have already commissioned the second pointcounterpoint feature that will debate the validity of the atypical depression diagnosis. We welcome ideas from members of the American College of Neuropsychopharmacology, as well as readers of the journal, for future pointcounterpoint article topics. As always, these articles are peer-reviewed by three independent reviewers and the articles and the rejoinders from the respective authors are also peer-reviewed. I look forward to obtaining feedback concerning this new feature as well as suggestions for future topics.
I would also like to take this opportunity to invite the readership to submit topics for Perspectives articles. These review articles generally appear as the first article in an issue, are particularly highly rated by the ACNP membership and the Editorial Board, and their popularity with the readership is evidenced by their large number of citations in the literature. As always, I am extremely interested in receiving feedback from all of you concerning the direction and state of our journal. 
